This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing intermediate-risk (IR) and high-risk (HR) non-muscle invasive bladder cancer (NMIBC) with a community physician

Ticker(s): TARA, ENGN, CGON, JNJ, URGN

Who's the expert?

Institution: Steinberg Urology

  • Board-certified minimally-invasive urologist practicing at Steinberg urology, private urological care.
  • Currently manages ~90 patients with NMIBC.
  • Has over 15 years of experience treating patients with various therapies for NMIBC. 

Interview Goal
This call will discuss a variety of therapies in development for the treatment of intermediate-risk (IR) and high-risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC).

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.